Oncology Brothers
@OncBrothers
Followers
12,552
Following
429
Media
585
Statuses
2,162
Practice changing 🗣 by community oncologists: Rohit Gosain @RoswellPark & Rahul Gosain @WilmotCancer . OwnViews & not medical advice.COI
Joined August 2021
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
#DARKMOON
• 131345 Tweets
Cataluña
• 111750 Tweets
#FatalTrouble
• 84687 Tweets
चुनाव आयोग
• 74951 Tweets
つばさの党
• 69852 Tweets
Illa
• 68702 Tweets
#Supernova_OutNow
• 66625 Tweets
#MEMORABILIA_OutNow
• 65647 Tweets
Puigdemont
• 56195 Tweets
PS 1
• 55706 Tweets
Teeth
• 52375 Tweets
Lucifer
• 40085 Tweets
家宅捜索
• 37240 Tweets
We Love Daddy Tay🩵
• 30882 Tweets
माधवी लता
• 23823 Tweets
Happy New Week
• 21056 Tweets
Kamuda Tasarruf
• 20445 Tweets
バンドリ
• 18235 Tweets
Lebih KEREN KitaKOMPAK
• 16906 Tweets
ミオしゃ
• 16337 Tweets
作者の顔
• 13668 Tweets
Mehmet Şimşek
• 12662 Tweets
SATs
• 10457 Tweets
Pinned Tweet
#GISeries
: Where are the
#RadOnc
&
#IRad
? Here they are…
Importance of collaboration/MultiD in
#gism
w/
@NiuSanford
@jryckman3
@ChengaziMD
Full 🗣️
-
-
- Also on “Oncology Brothers” podcast
#OncTwitter
#MedTwitter
@CancerNetwrk
This is the
#Algorithm
we have used during our discussion w/
@GIcancerDoc
for
#HCC
!
#OncTwitter
#MedTwtitter
#gism
#MedEd
@CancerNetwrk
#OncEd
#LiverCancer
6
37
113
0
15
29
Day 1
#ASCO23
Highlights:
1.
#NATALEE
: Adj
#ribociclib
HR+ breast Ca
2. MONARCHE: Adj
#abemaciclib
update
3.
#ATTRACTION5
: Adj Gastric Ca
4.
#IMbrave050
: Adj HCC
5. OFS in Premenopausal
6.
#IMerge
imetelstat MDS
@ASCO
@OncoAlert
#bcsm
#gism
#OncTwitter
#MedTwitter
1/7
11
159
507
#ASCO22
#PlenarySession
summary
1.
#DESTINYBreast04
: TDXd in low HER2 mBC
2.
#PARADIGM
: Pan + mFOLFOX6 vs Bev + mFOLFOX6 in mCRC
3.
#rEECur
: Topotecan, cyclophos & HD ifos in Ewing
#Sarcoma
4.
#DETERMINATION
: RVd +/- ASCT + Rev in myeloma
#BCSM
#CRCSM
#GISM
#MMSM
@OncoAlert
1/5
3
138
383
8 new drugs/indications were approved by
@FDAOncology
for Thoracic Malignancies in 2021!
We have created tables for indications and their results to stay organized and for a quick reference.
#MedTwitter
@OncoAlert
#OncTwitter
#LCSM
@IASLC
#lungcancer
#thyroidcancer
4
119
372
In 2021, 5 new drugs/indications were approved for GI malignancies by
@FDAOncology
:
- Ivosidenib
- Nivo in adj settings
- Nivo + chemo
- Pembro + chemo
- TDxd
Here is a summary!
#GastricCancer
#MedEd
@OncoAlert
@ASCO
#GIOncology
#CRCSM
#MedTwitter
#OncTwitter
#Oncology
4
131
354
< 3 weeks to
#ESMO23
, here is a📝 of 🔑abstracts for general onc that could change our SoC!
-
#ALINA
-
#LIBRETTO431
-
#TROPIONLung01
-
#MARIPOSA
-
#Ev302
-
#CM901
-
#LITESPARK005
-
#KN756
-
#CABINET
-
#CODEBREAK300
#BCSM
#GISM
#LCSM
#MedTwitter
#GUSM
#OncTwitter
@myESMO
13
114
317
Less than 2 weeks to
#ASCO23
, here is our list of what we anticipate could be practice-changing/reinforcing!
Please add if we left out that could change our practice post
@ASCO
@OncoAlert
#bcsm
#MedTwitter
#OncTwitter
#GISM
#lcsm
@TargetedOnc
@TotalHealthConf
@mydocwire
#gusm
7
82
310
We've been working on this table as each drug has its own approved IHC Assay & their own scoring method. Would love everyone to contribute to ensure its as comprehensive as possible
#GISM
#LCSM
@HemOncFellows
#BCSM
@NarjustFlorezMD
@JackWestMD
@ADesaiMD
#MedTwitter
@MPishvaian
12
92
247
Day 1
#ESMO23
Highlights
#CommunityOncology
NSCLS
1.
#CM816
@DrMarkAwad
2.
#KN671
@DoctorJSpicer
3.
#ATTLAS
Breast Ca
4.
#MonarchE
#bcsm
5.
#KN756
/
#CM7FL
@LoiSher
6.
#KN522
TNBC
@JavierCortesMD
#lcsm
#OncTwitter
@myESMO
#OncEd
@OncoAlert
@DrSGraff
@g_mountzios
1/7
6
82
229
Day 2
#ASCO23
Highlights:
1.
#KN671
: PeriOp pembro in resectable NSCLC
2.
#KN826
: Chemo + IO in cervical Ca
3.
#DUOO
: IO/PARPi ovarian cancer patients in 1L
#lcsm
@ASCO
@OncoAlert
#OncTwitter
#MedTwitter
#gyncsm
1/4
1
90
219
Day 1
#ESMO22
Highlights
#CommunityOncology
1.
#MONARCH3
in mBC
2.
#TROPiCS02
in mBC
@hoperugo
3. Understanding HER-2Low Breast Ca
@PTarantinoMD
@prat_aleix
4. mTNBC in 2022
@DrLisaCarey
5. Management of RCC
@ERPlimackMD
@myESMO
#MedTwitter
#OncEd
#bcsm
#GUSM
1/6
3
66
214
#AACR23
highlights, what we need to know as a community onc:
1.
#AEGEAN
: Periop ChemoIO + AdjIO -NSCLC
2.
#KN966
: Pembro/Gem/Cis -BiliaryCA
3.
#IMbrave050
: Adj Atezo/Bev -HCC
4.
#S1512
: Pembro-Desmoplastic
#Melanoma
#OncTwitter
@OncoAlert
#MedTwitter
@AACR
#lcsm
#gism
1/5
3
77
207
7 new drugs/indications were approved by
@FDAOncology
for lung cancer in 2022:
-
#Nivolumab
in neoadj
-
#Capmatinib
-
#TDxD
-
#Selpercatinib
-
#Adagrasib
- More IO options
Here is a summary table:
#MedTwitter
@OncoAlert
#OncTwitter
#LCSM
@IASLC
#lungcancer
#OncEd
#MedEd
8 new drugs/indications were approved by
@FDAOncology
for Thoracic Malignancies in 2021!
We have created tables for indications and their results to stay organized and for a quick reference.
#MedTwitter
@OncoAlert
#OncTwitter
#LCSM
@IASLC
#lungcancer
#thyroidcancer
4
119
372
4
59
210
Day 2
#ASCO22
Highlights
#CommunityOncology
perspective
1.
#DestinyBreast03
in mBC by
@ErikaHamilton9
2.
#PALOMA
2 update in mBC
3.
#TROPICS2
in mBC by
@hoperugo
4.
#DYNAMIC
: ctDNA guiding adjuvant Rx in CRC
#MedEd
#MedTwitter
@OncoAlert
@ASCO
1/5
3
72
206
#WCLC23
Highlights
#CommunityOncology
🔎:
1.
#IMPower133
update ES-SCLC
@StephenVLiu
2.
#DESTINYLung02
Her2 NSCLC
3.
#MARS2
: ✂️mesothelioma
@ekslim
4.
#FLAURA2
: 1L mEGFR
5. 2L mEGFR:
#CHRYSALIS2
#HERTHENALung01
6. TNM 9thEd
#lcsm
@IASLC
#OncTwitter
#MedTwitter
#MedEd
3
81
206
.
@FDAOncology
has been busy to say the least.
7 new drugs/indications were approved for GU Malignancies in 2021! Here is a table summarizing those findings.
#MedTwitter
#OncTwitter
#Oncology
#bladdercancer
#kidneycancer
#MedEd
@OncoAlert
@ASCO
@myESMO
7
88
198
< 2 weeks to
#ESMO22
, here is a list of what we anticipate that could be critical for general oncologists s/p
@myESMO
Inspired by
@DrChoueiri
,
@PTarantinoMD
,
@GillSharlene
#BCSM
#GISM
#LCSM
#OncEd
#MedTwitter
#GUSM
@HemOncFellows
@neerajaiims
@CathyEngMD
@FAndreMD
@hoperugo
3
68
196
What just happened? 5 new 💊/indications ✅ by
@FDAOncology
in the last 10 days. As
#CommunityOncologists
, we need to know them all:
1.
#Fruquintinib
in refractory mCRC, mPFS 3.7mos vs 1.8mos
2.
#Pembrolizumab
(+Chemo) in 1L mGEJ/Gastric Ca, mOS 12.9mos Vs 11.5mos…
9
75
195
2 weeks to
#ASCO22
, here is a list of what we anticipate could be practice changing. Pls add if we left a critical abstract out that could change our treatment s/p
@ASCO
Inspired by
@ErikaHamilton9
&
@DrChoueiri
@OncoAlert
#BCSM
#GISM
#LCSM
#OncEd
#MedTwitter
#Sarcoma
#GUSM
5
74
195
Day 4
#ASCO23
highlights
1.
#TALAPRO2
: PARPi + Enza in mCRPC
2.
#THOR
: Erdafitinib in FGFR urothelial cancer
3.
#VESPER
: ddMVAC Vs Gem/Cis PeriOp MIBC
4.
#CONTACT03
: Re-challenge IO in RCC
@ASCO
#OncTwitter
#MedTwitter
@OncoAlert
#Gusm
#KidneyCancer
#BladderCancer
1/9
1
84
182
Practical algorithm/landscape for treating patients with bladder cancer shared by
@apolo_andrea
during
#OncoAlertColloquium
and an updated algorithm by
@EUplatinum
. This should your SoC in the community!
#OncEd
#MedTwitter
@OncoAlert
1
72
181
Our 1000th tweet!!!
#Oncology
#OncologyBrothers
@ASCO
#Siblings
Cannot thank
#MedTwitter
#OncTwitter
&
#HemeTwitter
enough
How it started How it's going
13
12
183
#ESMO23
Day 3 Highlights
#CommunityOnc
:
1.
#CABINET
- NET
2.
#GASTFOX
- GEJ/mG
3.
#JCOG1611
- PancCa
#bladdercancer
4.
#CM901
@apolo_andrea
@MattGalsky
5.
#EV302
HISTORY IN MAKING! “GOOSEBUMPS” as
@DrChoueiri
said!
#gism
#gusm
#OncTwitter
#MedTwitter
@myESMO
1/6
2
67
181
Day 3:
#ASCO23
#Plenary
summary
1.
#INDIGO
: Vorasidenib in Glioma
2.
#PROSPECT
: NeoAdj ChemoXRT or FOLFOX —> TME in Rectal Ca
3.
#ADAURA
: Adj
#Osimertinib
in NSCLC
4.
@SWOG
#S1826
: Nivo or Bv + AVD in advanced cHL
#lcsm
#lymsm
#gism
@ASCO
#OncTwitter
#MedTwitter
@OncoAlert
2
79
176
Day 1
#ASCO22
Highlights
#CommunityOncology
perspective
1. Pooled analysis for mNSCLC, ICI Vs. chemo + ICI by
@FDAOncology
2. Outcomes of 1L KRASm NSCLC
3.
#ECHELON1
update
4. Launch of ASCO Med CoP
5.
#SHINE
- 1L MCL
#LCSM
#MedEd
#MedTwitter
#LymSM
@OncoAlert
1/6
1
45
169
Day 1
#GI23
Highlights
#CommunityOncology
1.
#NeoAGIS
: Chemo vs CROSS
2.
#Infinity
: NeoAdj IO dMMR G/GEJ Ca
3.
#SPOTLIGHT
: CLDN18.2 (Importance of NGS)- New SoC
4.
#INTEGRATEIIA
: Rego in pretreated pts
@ASCO
#OncEd
#MedEd
#Oncology
@OncoAlert
@HemOncFellows
#gism
3
52
168
Yet another busy year for
@FDAOncology
@US_FDA
. ≥40 new approvals/indications in 2023 for Heme-Onc.
Our end of year wrap-up tradition. Indications & study findings for the 5 approved 💊 in
#LungCancer
:
#lcsm
#MedTwitter
#OncTwitter
@VivekSubbiah
#precisionmedicine
#ret
#braf
2
55
150
#ESMO23
Day 4 Highlights
#CommunityOnc
:
1.
#CAIRO5
- mColorectal Ca
2.
#TROPIONBreast01
- HR+
#BreastCancer
3.
#PSMAfore
- mCRPC
#ProstateCancer
#LungCancer
4.
#TROPIONLung01
5.
#MARIPOSA
6.
#MARIPOSA2
#gism
#lcsm
#bcsm
#crcsm
#OncTwitter
@myESMO
#Medtwitter
1/7
1
54
152
Day 3
#GI23
Highlights
#CommunityOncology
1.
#MOUNTAINEER
: Tucat+Trast approved CRC
2.
#SUNLIGHT
: TAS102+Bev confirmed late option CRC
3.
#E2211
: Cape+Tem in pNET manuscript
4.
#ctDNA
kinetics CRC
5. TNT state in RectalCA
@ASCO
#OncEd
#MedEd
@OncoAlert
#GISM
#MedTwitter
2
61
147
3
@FDAOncology
approvals in less than 24 hours:
1.
#Pembrolizumab
adj NSCLC
2.
#Pirtobrutinib
refractory Mantle cell lymphoma
3.
#Elacestrant
HR+ mESR1 advanced breast CA
#CommunityOncology
@OncoAlert
@HemOncFellows
@US_FDA
#MedTwitter
#OncEd
#MedEd
3
36
147
This is the updated
#Algorithm
for
#BladderCancer
. Nivo/Gem/Cis was not approved at the time of this discussion w/
@DrKarineTawagi
and
@siadaneshmand
but has been incorporated in this is mage below.
#OncTwitter
#MedTwtitter
#gusm
#MedEd
@CancerNetwrk
#OncEd
#BladderCancer
algorithm, w/
@DrKarineTawagi
&
@siadaneshmand
to reiterate the current SoC for this disease:
Full Discussion:
-
-
- Also on the “Oncology Brothers” podcast
#OncTwitter
#MedEd
#gusm
@CancerNetwrk
#MedTwitter
0
7
36
4
63
138
This is the
#algorithm
we have used during our discussion for
#HR
positive
#breastcancer
w/
@VKaklamani
#bcsm
#onctwitter
#meded
#OncEd
#MedTwitter
#Oncology
@CancerNetwrk
#BreastCancer
algorithm series, w/
@VKaklamani
to reiterate the current SoC for HR+ Breast Cancer:
Full Discussion:
-
-
- Also on the “Oncology Brothers” podcast
#bcsm
#OncEd
#OncTwitter
#MedEd
@CancerNetwrk
#MedTwitter
1
16
37
4
53
143
This is the
#ProstateCancer
algorithm we have used during our discussion with
@DrRanaMcKay
#MedEd
#OncEd
#OncTwitter
#MedTwitter
#gusm
@CancerNetwrk
#ProstateCancer
algorithm, w/
@DrRanaMcKay
to reiterate the current SoC for this disease:
Full Discussion:
-
-
- Also on the “Oncology Brothers” podcast
#OncEd
#OncTwitter
#MedEd
#gusm
@CancerNetwrk
#MedTwitter
1
9
32
2
42
143
As we get ready for Day 3
#GI22
, here is an algorithm that was shared for metastatic colorectal cancer from
#CommunityOnc
’s perspective. Please recommend any updates/changes.
#CRC
#crcsm
#OncED
#MedTwitter
@NCCN
@OncoAlert
#oncology
5
55
137
Summary of 10 new indications/approvals in Heme Malignancies (excluding CART) by
@FDAOncology
in 2023:
1.
#Zanubrutinib
2.
#Pirtobrutinib
3.
#Polatuzumab
4.
#Epcortimab
5.
#Glofitamab
6.
#Quizartinib
7.
#Talquetamab
8.
#Elranatamab
9.
#Ivosidenib
#HemeTwitter
#MedTwitter
…
4
55
136
This is the updated
#algorithm
we used during our discussion w/
@DrGattiMays
for HR+
#BreastCancer
#sacituzumab
(or is it “sassy toucan”)
#elacestrant
#TDxD
#ERPositive
#bcsm
#OncTwitter
#OncEd
#MedTwitter
@OncoAlert
w/
@DrGattiMays
, we 🗣 the Rx algorithm for HR+ breast ca and the recent approvals.
Full Int:
-
- Also on “Oncology Brothers” 🎙
@PTarantinoMD
@JAMouabbi
and
@DrGattiMays
🙏🏽 for this
#breastcancer
series!
#bcsm
#MedTwitter
#OncTwitter
#OncEd
#MedEd
0
22
53
5
51
134
3 new drugs/indications were approved by
@FDAOncology
for Breast Cancer in 2021. Here is a summary!
#BCSM
Thank you
@ErikaHamilton9
@hoperugo
@stolaney1
@DrHBurstein
@DrNeilLove
@PeerView
@OncLive
for discussions/guidance on how to apply these indications in our practice
1
49
134
Day 1
#GU22
#prostateday
@asco
Summary (what we need to know for our clinics in the community tomorrow):
1.
#ARASENS
2.
#PROpel
3.
#MAGNITUDE
4.
#PRESIDE
#practicechanging
#prostatecancer
#MedTwitter
#OncEd
@OncoAlert
1/5
3
56
131
Summary of 5 new drugs/indications in GI malignancies that were
@FDAOncology
@US_FDA
approved in 2023:
-
#Tucatinib
- Mountaineer
-
#TAS102
+
#Bevacizumab
- Sunlight
-
#Pembro
+ Cis/Gem - KN966
-
#Fruquintinib
- FRESCO2
-
#Pembro
+ Chemo - KN859
#OncTwitter
#gism
#crcsm
Summary of the 4 new drugs/indications that were approved for GI malignancies by
@FDAOncology
in 2022:
- Nivo & Ipi/Nivo
- Durvalumab
- Futibatinib
- Treme + Durva
#GastricCancer
#MedEd
@OncoAlert
@ASCO
#GIOncology
#CRCSM
#MedTwitter
#OncTwitter
#Oncology
#gism
1
45
118
2
53
129
#SABCS23
Day 2 Highlights
#CommunityOnc
:
HR+
1. Update
#CM7FL
+
#KN756
2.
#MONARCH3
3.
#HER2CLIMB02
(Her2+)
4. Role of Anthracyclines
5.
#OLAnzaPiNE
(all solid tumors)
1/6
#bcsm
#OncTwitter
@SABCSSanAntonio
@AACR
@UTHealthSAMDA
#BreastCancer
#MedTwitter
@ThanksCancer
3
50
129
#Durvalumab
@US_FDA
approved for advanced biliary tract cancer
#TOPAZ1
Ph3, 1L Durva + Gem/Cis vs. Gem/Cis
- New SoC
- OS (HR: 0.80) and PFS (HR0.75) with addition of Durva
- Benefit seen regardless of PDL1. 2yr OS: 24.9% Vs 10.4%
#GISM
@OncoAlert
@pashtoonkasi
#MedTwitter
8
36
128
#ASH23
Highlights
#CommunityOnc
:
#Myeloma
1.
#PERSEUS
2.
#IsKia
3.
#Bortezomib
dosing
CLL Update
4.
#SEQUOIA
&
#ALPINE
cHL Update
5.
#SWOGS1826
MF
6.
#TRANSFORM1
&
#MANIFEST2
1/7
#HemeTwitter
#OncTwitter
#MedEd
#AMLsm
#MMsm
#MDSsm
@ASH_hematology
@SWOG
5
49
123
Day 1
#GI24
@ASCO
Highlights
#CommunityOncology
1.
#KN590
update
2.
#Docetaxel
+ FOLFOX in 1L GEJ/gastric AdenoCa
3. PeriOp IO in:
- GEJ/Gastric (
#MATTERHORN
)
- LA-ESCC (
#ESCORTNEO
)
4.
#SKYSCRAPER08
(anti-TIGIT) in mESCC
#OncEd
#MedEd
#OncTwitter
#MedTwitter
#gism
1/6
1
49
124
< 72 hrs to
#SABCS23
, here is a📝 of 🔑abstracts from
#CommunityOncologists
perspective.
🙏🏽🙏🏽🙏🏽
@SABCSSanAntonio
@AACR
for selecting us to serve as SABCS 2023 Social Media Supporter!
Stay tuned for EOD highlights!
#MedEd
#bcsm
#OncTwitter
@UTHealthSAMDA
#breastcancer
5
41
125
Neoadj Nivolumab + Chemo now
@FDAOncology
approved for NSCLC.
#CM816
: Ph3, N= 358, Neoadjuvant, Nivo + Chemo Vs Chemo alone, resectable IB-IIIA NSCLC
- pCR of 24% vs 2% with Nivo
- improved EFS
@OncoAlert
#LCSM
@ASCO
#MedTwitter
#OncEd
3
45
121
3 new drugs/indications were approved by
@FDAOncology
for Breast Cancer and 2 for Gyn Onc in 2022. Here is a summary!
-
#TDXd
x 2
-
#Olaparib
-
#Pembrolizumab
-
#Mirvetuximab
#bcsm
#gynsm
@OncoAlert
#breastcancer
#MedTwitter
#OncEd
#MedEd
#ovariancancer
0
40
121
Summary of the 4 new drugs/indications that were approved for GI malignancies by
@FDAOncology
in 2022:
- Nivo & Ipi/Nivo
- Durvalumab
- Futibatinib
- Treme + Durva
#GastricCancer
#MedEd
@OncoAlert
@ASCO
#GIOncology
#CRCSM
#MedTwitter
#OncTwitter
#Oncology
#gism
In 2021, 5 new drugs/indications were approved for GI malignancies by
@FDAOncology
:
- Ivosidenib
- Nivo in adj settings
- Nivo + chemo
- Pembro + chemo
- TDxd
Here is a summary!
#GastricCancer
#MedEd
@OncoAlert
@ASCO
#GIOncology
#CRCSM
#MedTwitter
#OncTwitter
#Oncology
4
131
354
1
45
118
#Talazoparib
+ Enza now
@FDAOncology
approved 1L, mCRPC HRR deficient
#TALAPRO2
:
- Improved rPFS in all comers (HR 0.45)
- rPFS was higher in BRCA 1/2
- OS immature, but 📈 towards survival
Congratulations
@neerajaiims
et Al.
#gusm
@OncoAlert
#OncTwitter
#MedTwitter
#brca
3
48
119
#ESMO23
Day2 ⚡️🔥
#CommunityOncology
1. DB04 ⬇️Her2
#bcsm
#NSCLC
2.
#ALINA
ALK+
@bensolomon1
3.
#LIBRETTO431
RET+
4.
#PAPILLON
Exon20
5.
#CM77T
✂️
6.
#LITESPARK005
Belzutifan-RCC
@DrChoueiri
7.
#SPOTLIGHT
Cldn18.2
#gism
#OncTwitter
#MedTwitter
@myESMO
#lcsm
1/8
2
54
118
This is the algorithm we used during our discussion with
@CathyEngMD
to go over the current landscape of
#ColonCancer
#crcsm
#GITwitter
#MedEd
@OncoAlert
@OncoJurdi
#OncTwitter
#MedTwitter
@pashtoonkasi
@SKamath_MD
@GIcancerDoc
@TumorBoardTues
w/
@CathyEngMD
, we 🗣 the Rx algorithm for
#ColonCancer
and the pending
#Fruquintinib
approval.
Full Int:
-
- Also on the “Oncology Brothers” podcast 🎙️
@OncoAlert
@GIcancerDoc
#gism
@HemOncFellows
@VUMCHemOnc
#crcsm
#OncTwitter
#MedTwitter
#OncEd
0
16
68
6
41
115
Day 1
#GU23
#ProstateCacer
Highlights
#CommunityOncology
1.
#TALAPRO2
: mCRPC PARPi 1L
@neerajaiims
2.
#TRITON3
: mCRPC PARPi 2L
@AlanBryce9
3.
#ARASENS
update Dara+Doce 1L
4.
#PROPEL
update PARPi 1L
@ASCO
#OncEd
#MedEd
@OncoAlert
#GUSM
#MedTwitter
1
42
117
Roadmap for Early TNBC and for Metastatic TNBC by
@hoperugo
(thanks
@ErikaHamilton9
and
@DrSGraff
for sharing). Amazing summary/algorithms that we can easily follow in our community settings
#SABCS21
#bcsm
1
46
114
This is the
#Algorithm
we have used during our discussion w/
@KlempnerSam
for
#UpperGI
- Testing for MSI, Her 2, CPS (and soon Cldn18.2) is critical!
#OncTwitter
#MedTwtitter
#gism
#MedEd
@CancerNetwrk
#OncEd
GI Series:
#UpperGi
algorithm, w/
@KlempnerSam
to reiterate the current landscape:
Full Discussion:
-
-
- Also on the “Oncology Brothers” podcast
#OncTwitter
@CancerNetwrk
#MedTwitter
#GISM
2
16
45
2
38
114
#SABCS23
Day 4 Highlights
#CommunityOnc
:
1.
#NATALEE
update
2.
#INAVO120
3.
#KN522
update
4.
#KATHERINE
update
5. Summary by
@IlanaSchlam
1/5
#bcsm
#OncTwitter
@SABCSSanAntonio
@AACR
@UTHealthSAMDA
#BreastCancer
#MedTwitter
#OncEd
#Oncology
@VKaklamani
4
45
112
This is the
#Algorithm
we have used during our discussion w/
@GIcancerDoc
for
#HCC
!
#OncTwitter
#MedTwtitter
#gism
#MedEd
@CancerNetwrk
#OncEd
#LiverCancer
GI Series:
#HCC
algorithm, w/
@GIcancerDoc
to reiterate the current landscape:
Full Discussion:
-
-
-Also on the “Oncology Brothers” podcast
-🗣️
@aparna1024
&
@KlempnerSam
to follow.
#OncTwitter
@CancerNetwrk
#MedTwitter
#GISM
0
8
33
6
37
113
Day 2
#GI24
@ASCO
Highlights
#CommunityOncology
1.
#IMbrave151
2. GI/ColoRectal Ca in young adults
3.
#ALPACA
4.
#EXTEND
5.
#NETTER2
6.
#EMERALD1
#OncEd
#MedEd
#OncTwitter
#MedTwitter
#gism
#crcsm
#pancsm
1/7
4
43
112
Breast Cancer Highlights from
#ASCO23
w/
@DrSGraff
-
#NATALEE
-
#SONIA
- X-7/7
Full Int:
-
- Also on “Oncology Brothers” podcast
#bcsm
@ASCO
@PTarantinoMD
#OncTwitter
#MedTwitter
@ErikaHamilton9
@DrGattiMays
@DrLoveResearch
@TargetedOnc
#MedEd
0
54
109
Tumor agnostic approvals are becoming more common. 4 new drugs/indications were approved by
@US_FDA
@FDAOncology
for mutation driven malignancies and 3 for skin/soft tissue cancers, here is a summary!
#BRAF
#RetFusion
#PrecisionMedicine
#MedTwitter
#OncEd
#MedEd
@OncoAlert
1
41
111
#Alectinib
now
@FDAOncology
approved based off
#ALINA
trial.
Alectinib vs Chemo post resection in NSCLC, Stg Ib-IIIA:
- Alectinib for 2 yrs
- Improved DFS in all subgroups: HR0.24
- Improved CNS DFS HR: 0.22
- New Soc
@bensolomon1
#lcsm
#onctwitter
#medtwitter
1
42
110
#SABCS23
Day 1 Highlights
#CommunityOnc
:
@FDAOncology
Review on recent approvals
1.
#CAPItello291
2.
#EMERALD
3.
#TDxD
4. Tumor Agnostic landscape
5. Post CDK4/6i HR+
@SABCSSanAntonio
@VivekSubbiah
@VKaklamani
@JaniceTNBCmets
#bcsm
@DrSGraff
@oreganruth
1/6
2
42
108
#Fruquintinib
is now
@FDAOncology
approved based
#FRESCO2
in refractory mCRC (discussed this w/
@CathyEngMD
previously, link👇).
- mOS 7.4mos vs 4.8mos (HR=0.66)
- ORR: 16% vs 1.5%
- mPFS 3.7mos vs 1.8mos
- New treatment option for our refractory mCRC Pts!
#crcsm
#OncTwitter
w/
@CathyEngMD
, we 🗣 the Rx algorithm for
#ColonCancer
and the pending
#Fruquintinib
approval.
Full Int:
-
- Also on the “Oncology Brothers” podcast 🎙️
@OncoAlert
@GIcancerDoc
#gism
@HemOncFellows
@VUMCHemOnc
#crcsm
#OncTwitter
#MedTwitter
#OncEd
0
16
68
2
29
106
Quarter 1, 2022 Oncology Earnings Report
#PracticeChanging
studies/approvals so far🧵
1.
#LuPSMA
approved for Prostate Cancer
2.
#DESTINYBreast03
TDXd superior to TDM-1 2L Her2+ mBC
3.
#Pembro
approved for 2L MSI-H endometrial CA
#OncTwitter
#OncEd
#MedTwitter
@OncoAlert
5
54
105
So much has changed in such a short time for HER2+
#breastcancer
. To continue our series,
@ErikaHamilton9
walks us through the algorithm to reiterate SoC in the community for HER2+ breast CA:
-
-
#bcsm
#MedTwitter
#OncMedEd
5
22
104
#Amivantamab
now
@FDAOncology
approved for mNSCLC Exon20 based off
#PAPPILON
in 1L w/ chemo:
- PFS 11.4mos w/Ami vs 6.7mos chemo (HR: 0.40)
- ORR in 73% vs 47%
- OS favoring Ami (HR: 0.67)
- 7%⛔Ami because of AEs
- New SoC/Practice Changing
#lcsm
#onctwitter
#medtwitter
1
36
100
This is the
#algorithm
we have used during our discussion for
#TNBC
w/
@oreganruth
&
@AnnaWeissMD
#bcsm
#OncTwitter
#MedTwitter
#OncEd
#BreastCancer
@CancerNetwrk
#BreastCancer
algorithm series, starting off w/
@oreganruth
&
@AnnaWeissMD
to reiterate the current SoC for TNBC:
Full Discussion:
-
-
- Also on the “Oncology Brothers” podcast
#bcsm
#OncEd
#OncTwitter
#MedEd
@CancerNetwrk
3
13
21
1
32
98
In 2023, 3 more drugs/indications were approved for
#BreastCancer
by
@FDAOncology
@US_FDA
:
-
#Elacestrant
in ESR1 HR+
-
#Sacituzumab
in endocrine resistant HR+
-
#Capivasertib
in AKT1/PIK3CA/PTEN mutation HR+
#bcsm
#OncTwitter
#MedTwitter
#oncology
@ThanksCancer
3 new drugs/indications were approved by
@FDAOncology
for Breast Cancer and 2 for Gyn Onc in 2022. Here is a summary!
-
#TDXd
x 2
-
#Olaparib
-
#Pembrolizumab
-
#Mirvetuximab
#bcsm
#gynsm
@OncoAlert
#breastcancer
#MedTwitter
#OncEd
#MedEd
#ovariancancer
0
40
121
0
41
98
#WCLC22
Highlights
#CommunityOncology
perspective:
1.
#YESS
Study -
@RachM_UoN
2.
#IMPower010
Update
3.
#CALGB140503
- Sublobar resection
4.
#SHAWL
Study -
@NarjustFlorezMD
@jillfeldman4
5.
#NADIM2
Trial by
@MARIANOPROVENCI
1/6
#LCSM
#MedTwitter
@OncoAlert
#OncEd
@IASLC
2
46
97
This is the
#Algorithm
we have used during our discussion w/
@aparna1024
on
#ColonCancer
- Clinical Trials should ALWAYS be on our radar!
#OncTwitter
#MedTwtitter
#gism
#MedEd
@CancerNetwrk
#OncEd
#crcsm
GI Series:
#ColonCancer
algorithm, w/
@aparna1024
to reiterate the current landscape:
Full Discussion:
-
-
-Also on the “Oncology Brothers” podcast
#OncTwitter
@CancerNetwrk
#MedTwitter
#GISM
#crcsm
0
14
47
4
33
94
This is the
#KidneyCancer
algorithm we have used during our discussion with
@montypal
#MedEd
#OncEd
#OncTwitter
#MedTwitter
#gusm
@CancerNetwrk
#KidneyCancer
algorithm, w/
@montypal
to reiterate the current SoC for this disease:
Full Discussion:
-
-
- Also on the “Oncology Brothers” podcast
#OncEd
#OncTwitter
#MedEd
#gusm
@CancerNetwrk
#MedTwitter
#RCC
@cityofhope
2
10
33
1
28
91
This is the
#algorithm
we have used during our discussion for
#Her2
positive
#BreastCancer
w/
@DrHBurstein
#bcsm
#OncTwitter
#MedTwitter
#OncEd
#BreastCancer
@CancerNetwrk
#BreastCancer
algorithm series, w/
@DrHBurstein
to reiterate the current SoC for Her2+:
Full Discussion:
-
-
- Also on the “Oncology Brothers” podcast
#bcsm
#OncEd
#OncTwitter
#MedEd
@CancerNetwrk
#MedTwitter
3
8
28
3
29
91
This is the
#algorithm
we had used during our discussion with
@DrSapnaPatel
to go over the current landscape of
#melanoma
We have incorporated the recent
#Nivolumab
approval in this algorithm for adjuvant Stg IIB/C
#MedEd
#Oncology
#MedTwitter
#OncTwitter
#OncEd
@OncoAlert
w/
@DrSapnaPatel
we🗣️SoC for
#Melanoma
& key📝 to focus on in the community:
- Adj IO Vs BRAF-MEKi
- Switch Rx
-
#CTLA4
Full discussion:
-
- Also on the “Oncology Brothers” podcast
#MedTwitter
#OncTwitter
#OncEd
#Oncology
@CureMelanoma
@SWOG
0
6
18
2
22
91
Day 1
#GU24
@ASCO
Highlights
#CommunityOncology
1.
#CONTAC02
: Atezo/Cabo mCRPC
2.
#BRCAAWAY
: PARPi in mCRPC
3.
#EMBARK
: High Risk biochemical recurrence
#ProstateCancer
cancer
#OncEd
#MedEd
#OncTwitter
#MedTwitter
#gusm
1/4
2
34
90
2 weeks to
@SABCSSanAntonio
, here is a list of our "top" anticipated practice-informing studies for the community onc. Looking forward to accredited conference highlights with our expert faculty after
#SABCS22
#bcsm
#MedTwitter
@SoMeCME
#OncEd
#MedEd
@OncoAlert
#breastcancer
0
37
90
To reiterate the SoC for
#bladdercancer
,
@apolo_andrea
walks us through this Rx algorithm.
To complete the series,
#ProstateCancer
w/
@neerajaiims
soon.
Full Int:
-
- Also on “Oncology Brothers” podcast
#gusm
#MedTwitter
#OncEd
#MedEd
@OncoAlert
4
26
90
#Capivasertib
now
@FDAOncology
approved w/ AKT alteration based off:
#CAPItello291
: Capi + Fulvestrant vs Fulvestrant + Placebo
- ⬆️ PFS w/ capivasertib 7.2mos vs 3.6mos (HR 0.60)
- Pending OS
- 400mg BID, 4days on/3days off
- Diarrhea a big SE
#bcsm
#MedTwitter
#OncTwitter
2
33
88
Time to re-visit the “Roadmap” for mTNBC by
@hoperugo
as she presents at
#OncoAlertColloquium
#BCSM
@OncoAlert
#MedTwitter
#OncEd
#MedEd
1
38
89
Day 4
#ASCO22
highlights
#CommunityOncology
perspective
1.
#CAIRO5
: FOLFOXIRI + bev vs. FOLFOX/FOLFIRI + bev in
#CRCSM
2. Ribociclib dose reduction impact on OS,
#MONALEESA2
3.
#VISION
: Ga-PSMA-PET in mCRPC
#BCSM
#PCSM
@OncoAlert
1/4
4
30
86
Day 2
#GI23
Highlights
#CommunityOncology
1.
#SOURCE
: Adj TACE+Sorafenib in HCC (Press Release for
#IMbrave050
)
2.
#RTOG1112
: SBRT + Sorafenib in HCC
3.
#NAPOLI3
: Liposomal Irinotecan in 1L pancreatic cancer
@ASCO
#OncEd
#MedEd
#Oncology
@OncoAlert
@HemOncFellows
#GISM
2
39
84
Nivo/Gem/Cis now
@FDAOncology
approved for 1L metastatic
#bladdercancer
based off
#CM901
:
- Improved OS w/ Nivo (HR 0.78) 21.7mos Vs 18.9mos
- ≥ Gr3 AEs in 62% Vs 52%
- New Option (if a patient is not a candidate for EV302)
#OncTwitter
#MedTwitter
#gusm
#OncEd
2
31
82
We are thrilled & honored to join this exceptional crew as a
#ASCO23
Featured Voice! Get ready for practice-changing highlights tailored for our community/general medical oncologists.
#OncTwitter
#MedTwitter
#lcsm
#bcsm
#gism
#gusm
@ASCO
#OncMedED
#MedEd
6
7
84
These are the algorithms we used during our discussions for the series of
#LungCancer
#lcsm
#MedTwitter
#Oncology
#OncTwitter
@HemOncFellows
#OncEd
@esinghimd
@DrJNaidoo
@CharuAggarwalMD
@Latinamd
@ADesaiMD
@JackWestMD
@StephenVLiu
@NarjustFlorezMD
@ThanksCancer
@jillfeldman4
With
@DrJNaidoo
, we 🗣 the Rx algorithm for metastatic
#LungCancer
w/🎯mutation in 1L.
Full Int:
-
- Also on “Oncology Brothers” 🎙
🙏🏽
@Latinamd
@CharuAggarwalMD
@esinghimd
+
@DrJNaidoo
for this series!
#lcsm
#MedTwitter
#PrecisionMed
#OncTwitter
1
8
53
4
23
81
#Sacituzumab
now
@FDAOncology
approved for HR+ mBC after endocrine + ≥2 lines of systemic rx
#TROPiCS02
: Ph3, n=543
- PFS HR: 0.66 & OS: 0.79
@DrSGraff
“OS in heavily pretreated HR+… is a celebration”
#bcsm
#MedTwitter
#OncTwitter
#MedEd
#oncology
0
21
79
#CarboShortage
: list of alternative regimens that group here at
@WilmotCancer
has put together as a gudiance.
Appreciate any additional thoughts. 🙏🙏
@antonyruggeri
&
@shycollie
for sharing your 📖.
@OncoAlert
#gism
#gusm
#OncTwitter
#lcsm
#bcsm
@DrJFriedberg
@oreganruth
4
39
81
Day 3
#ESMO22
Highlights
#CommunityOncology
1.
#CAIRO5
- unresec. CRC w/ liver mets
2.
#PROpel
Update - mCRPC
3.
#PRESTO
- M0 HSPC
4.
#ADAURA
Update - Adj NSCLC
5.
#NICHE2
- neoadj IO in Colon Ca
1/6
@myESMO
#MedTwitter
#OncEd
@OncoAlert
#GISM
#GUSM
#LCSM
@HemOncFellows
1
36
81
Day 3
#GI24
@ASCO
Highlights
#CommunityOncology
1.
#ctDNA
:
-
#BESPOKE
-
#GALAXY
-
#COBRA
2.
#CM8HW
: ICI in MSI-H/dMMR 1L CRC
3.
#SuppOnc
:
#Sexualhealth
#QoL
#PatientReportedOutcomes
#OncEd
#MedEd
#OncTwitter
#MedTwitter
#gism
#crcsm
1/4
1
30
79
#Selpercatinib
now
@US_FDA
approved for ALL metastatic solid tumors w/ RET fusion +ve. Congratulations
@VivekSubbiah
- ORR 44%, 2 CR and 16 PR
- DOR 24.5 mOS
- Testing for actionable mut. is the key!
@OncoAlert
#MedTwitter
#OncEd
@HemOncFellows
0
18
77
Our 2000 tweet!!!
#OncologyBrothers
@ASCO
#SiblingsinMedicine
#Oncology
Cannot thank
#MedTwitter
#OncTwitter
#bcsm
#gism
#gusm
#lcsm
#lymsm
#mmsm
&
#HemeTwitter
enough for all your support 🙏🏽🙏🏽🙏🏽
How it started How it's going
8
3
79
3
4
78
Practice changing/informing studies from
@ASCO
#GI23
for community oncologists w/
@marklewismd
:
-
#SPOTLIGHT
-
#NAPOLI3
- 5FU bolus
-
#SUNLIGHT
Full Interview:
-
- Also on “Oncology Brothers” podcast
@OncoAlert
#OncEd
#MedTwitter
#gism
#coloncancer
2
28
76
Day 4
#ESMO22
Highlights from
#CommunityOncologists
perspective:
1.
#IFCT1701
- ICI in mNSCLC
2.
#POSEIDON
Update - mNSCLC
@MLJohnsonMD2
3.
#CodeBreak200
- KRAS G12C NSCLC
@MLJohnsonMD2
#LCSM
#MedTwitter
#OncEd
@HemOncFellows
@OncoAlert
@myESMO
1/9
1
38
78
ASCO Plen: Ipi + Nivo —> Nivo and then BRAF/MEK inhib for BRAF+ melanoma has better OS.
2 yr OS: 72% (IO first) vs 52%
Would this be true for single agent IO? Should CTLA4 always be part of BRAF positive patients?
@ASCO
@OncoAlert
@OmidHamidMD
@jasonlukemd
#Melanoma
@OncLive
6
32
77
#LiposomalIrinotecan
now
@FDAOncology
approved for 1L metastatic
#PancreaticCancer
based off
#NAPOLI3
: NALIRIFOX vs. Gem/Abrax
- mOS 11.1mos Vs 9.2mos (HR: 0.83)
- Cross trial comparison, similar OS w/ FOLFIRINIOX
- Save liposomal for later lines?
#gism
#pancsm
#OncTwitter
7
24
76
w/
@VincentRK
, we 🗣 risk stratification + monitoring for
#MGUS
and to treat or not to treat
#SmolderingMyeloma
Full discussion:
-
- Also on the “Oncology Brothers” podcast 🎙️
#MedEd
#HemeTwitter
@HemOncFellows
#MedTwitter
#MMsm
@mydocwire
#Myeloma
1
33
75
We are where we are because of our
#Mentors
.
In collaboration with
@ASCO
,
@OncMedEdCoP
has launched a virtual mentoring program for medical educators
#MedEd
. Please sign up before January 8th as a Mentor or a Mentee:
#MedEd
varies for physicians in…
6
28
72
Treatment landscape for resectable NSCLS is quickly changing. Discussion/group effort by led
@ASridharMD
@IvyLorena_Md
@ArpanAshokPatel
to reiterate the current SoC!
@FordePatrick
thank you for ICER table! 🙏🏽🙏🏽
#lcsm
#ASCODailyNews
@ASCO
#OncTwitter
#ASCO24
#MedTwitter
2
33
73
KN564: Pembro was approved for high risk adj RCC in Nov 2021 based off this study. Now on
@NEJM
w/ OS benefit.
- DFS HR: 0.72 and OS HR: 0.62
- At 48 mos, OS 91.2% w/
#Pembrolizumab
vs 86%
-
@DrChoueiri
@TiansterZhang
@tompowles1
et al. 👏👏👏
#OncTwitter
#MedTwitter
#GUSM
3
28
72